BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pallotta S, Pace F, Marelli S. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related disease. Expert Review of Gastroenterology & Hepatology 2014;2:509-22. [DOI: 10.1586/17474124.2.4.509] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Marelli S, Pace F. Rabeprazole for the treatment of acid-related disorders. Expert Rev Gastroenterol Hepatol. 2012;6:423-435. [PMID: 22928894 DOI: 10.1586/egh.12.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
2 Ren L, Lu H, Li HY, Zhu LY, Xu XQ, Gu LY, Ge ZZ, Li XB. New dual therapy for primary treatment of Helicobacter pylori infection: A prospective randomized study in Shanghai, China. J Dig Dis. 2014;15:622-627. [PMID: 25205201 DOI: 10.1111/1751-2980.12186] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
3 Raha S, Mohanta D, Ahmaruzzaman M. Novel CuO/Mn3O4/ZnO nanocomposite with superior photocatalytic activity for removal of Rabeprazole from water. Sci Rep 2021;11:15187. [PMID: 34312406 DOI: 10.1038/s41598-021-94066-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
4 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract. 2013;2013:327571. [PMID: 24106498 DOI: org/10.1155/2013/327571] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Xia XM, Wang H. Gastroesophageal Reflux Disease Relief in Patients Treated with Rabeprazole 20 mg versus Omeprazole 20 mg: A Meta-Analysis. Gastroenterol Res Pract 2013;2013:327571. [PMID: 24106498 DOI: 10.1155/2013/327571] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
6 Shen T, Jiang X, Jin Z, Ji Q, Li C, Li Q, Long H, Qiu W, Wang W, Hou X, You J. The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors. European Journal of Pharmaceutics and Biopharmaceutics 2020;149:135-44. [DOI: 10.1016/j.ejpb.2020.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Sheng YC, Wang K, He YC, Yang J, Zheng QS. Effect of CYP2C19 genotypes on the pharmacokinetic/pharmacodynamic relationship of rabeprazole after a single oral dose in healthy Chinese volunteers. Eur J Clin Pharmacol 2010;66:1165-9. [PMID: 20838991 DOI: 10.1007/s00228-010-0892-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
8 Wang YL, Hsu LF. Evaluating the Feasibility of Use of a Foreign Reference Product for Generic Drug Applications: A Retrospective Pilot Study. Eur J Drug Metab Pharmacokinet 2017;42:935-42. [PMID: 28283987 DOI: 10.1007/s13318-017-0409-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]